Why the study?
Does psiepsilonRACK provide cardio-protection from ischemia in isolated cardiomyocytes and mouse hearts?
Does psiepsilonRACK provide cardio-protection from ischemia in isolated cardiomyocytes and mouse hearts?
An epsilonPKC-selective agonist octapeptide, psiepsilonRACK, provides sustained in vivo cardiac protection from ischemia, suggesting a potential therapeutic approach.
Hypothesis-generating for epsilonPKC agonism in ischemia; leaves open translation to human therapy.
Brief periods of cardiac ischemia trigger protection from subsequent prolonged ischemia (preconditioning). epsilon Protein kinase C (epsilonPKC) has been suggested to mediate preconditioning. Here, we describe an epsilonPKC-selective agonist octapeptide, psiepsilon receptor for activated C-kinase (psiepsilonRACK), derived from an epsilonPKC sequence homologous to its anchoring protein, epsilonRACK. Introduction of psiepsilonRACK into isolated cardiomyocytes, or its postnatal expression as a transgene in mouse hearts, increased epsilonPKC translocation and caused cardio-protection from ischemia without any deleterious effects. Our data demonstrate that epsilonPKC activation is required for protection from ischemic insult and suggest that small molecules that mimic this epsilonPKC agonist octapeptide provide a powerful therapeutic approach to protect hearts at risk for ischemia.
No takes yet. Share an insight, caveat, or question.
Dorn et al. (1999) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: